Ufp Technologies, Inc. · NASDAQ:UFPT
Ufp Technologies — Investor Presentation (June 2025)
27 slides from Ufp Technologies's investor presentation, June 2025
Slide 1: Welcome Investors
WelcomeInvestors Welcome Investors June March2025 2022
Slide 2: Forward Looking Statements
Forward Looking Statements Some of the statements contained in this Report are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). Management and representatives o
Slide 3: Who We Are
Who We Are Key Stats: Headquarters: Ticker: Established: Newburyport, MA UFPT 1963 UFP Technologies is a contract development and manufacturing organization (CDMO) that specializes in single use polymer Annual Revenue: Market Cap: 26 of top 30 based, medical devices ~$600 million 1 ~$1.85 Billion2 M
Slide 4: Shaping Innovation
Design & engineering capabilities Materials expertise Shaping Innovation Precision manufacturing Strategic locations 4
Slide 5: Our Process
Customer Design & Development POSSESS Tooling Our Process Custom Quality Pilot Commercial Equipment Systems Manufacturing Production LE a)
Slide 6: Product Development Business
Product Development Business High Margin Added Expertise 1 2 We bring deep experience in flexible material-based device manufacturing, from components and packaging, to BENEFITS final device assembly 3 4 Long Term Stronger Customer Relationships Manufacturing 6
Slide 7: MedTech Portfolio
MedTech Portfolio Robotic Drapes Revascularization Needleless Injection Device Port Cleaner MedSurg Bed Negative Pressure Patient Safety Wound Therapy 7
Slide 8: MedTech
MedTech MedTech Revenue by Segment3 $518 billion, 6.3% CAGR1 Global Medical Device Market Customers include 26 of the top 30 largest medical device manufacturers in the world2 Packaging 16% Global Medical Device CDMO Market4: $101B | 11% CAGR Devices UFP is uniquely focused on three RAS 58% medical
Slide 9: Medical Segment Overview
Medical Segment Overview $518 Billion Global Device Market, 6.3% CAGR1 Therapeutic Area Market % of Sales2 Growth Robotic Surgery 26% High Teens Surfaces & Support 25% LDD Interventional & Surgical 20% LSD Infection Prevention 10% MSD Orthopedics 5% MSD Therapeutics 4% MSD Wound Care 4% MSD Diagnost
Slide 10: Surrounding a High-Growth End Market: Robotic Surgery
Surrounding a High-Growth End Market: Robotic Surgery ROBOTIC SURGERY BY THE NUMBERS Acquisition strategy centered upon UFPT is the leading provider of several adding core capabilities to our • Market Size: ~$11B (2024) → ~$23.7B (2029)1 materials / capabilities that are critical for robotic surgery
Slide 11: Growth Strategy
Growth Strategy TWO-PRONGED Internal Growth: Strategic Acquisitions Market To Our Sweet Spot 11
Slide 12: Organic Growth Opportunity
Market to our sweet spot and differentiated capabilities » Leverage technology differentiation » Engineering resources » Exclusive access to specialty materials » Scale (footprint, clean room manufacturing) Organic Expand business with existing customers Growth » Offer complementary products and ser
Slide 13: Acquisition Growth Opportunity
Continue to Focus on Higher-Growth, Higher-Margin MedTech Opportunities that Create Value » Become more valuable to our customers » Strategic focus – new capability, geography, growing market segment, materials Acquisition » Add scale Growth » Look for synergistic opportunities » Cultural fit Opport
Slide 14: M&A Strategy Centered Upon Customer Needs
M&A Strategy Centered Upon Providing Enhanced Capabilities Based On Our Customer Needs • Rationale: Geographic expansion servicing • Rationale: Capabilities expansion existing MedTech customers in Ireland • Strategic Benefit: New capabilities play into our • Strategic Benefit: Custom-engineered foam
Slide 15: Proven Acquisition Integration Model
Proven Acquisition Proven Acquisition Integration Integration Model Model MedTech Sales over time 600,000,000 $451 million MedTech 500,000,000 $132 million MedTech 400,000,000 300,000,000 200,000,000 100,000,000 0 2021 2022 2023 2024 Medical Sales UFP Annual Sales Executing Strategy for performance
Slide 16: Why Invest?
Why Invest? Significant Barriers Strong Experienced Proven Attractive market to entry customer management growth financial growth relationships team strategy metrics opportunities 16
Slide 17: Significant Market Growth Opportunities
Focused on fast growing segments Significant Market Growth Market Focused On » Better Patient Outcomes Opportunities » Infection Prevention » Reducing Healthcare Costs Global Footprint » Bringing New Opportunities 17
Slide 18: Competitive Advantage
Competitive Advantage Greater Access to Engineering Resources Custom Equipment Materials » Veteran engineering team for » Exclusive access to several specialty » In-house custom equipment product design and development; medical grade materials manufacturing capabilities more than 100 members of the
Slide 19: Proven Growth Strategy
Proven Growth Creating Shareholder Value Strategy 19
Slide 20: Financial Targets
Financial Targets 20
Slide 21: Financial Targets
Financial Targets 3 to 5 Year Financial Targets 12-18% 28-31% 17-20% Revenue Growth Gross Margin Adjusted Operating Margin 21
Slide 22: Revenue
Revenue $600 $500 $400 $300 12% to 18% Targeted $200 Revenue Growth Internal Growth + $100 Acquisitions $0 2020 2021 2022 2023 2024 March 2025 TTM TTM = 12-month period ended March 31, 2025 22
Slide 23: Gross Profit Margin
Gross Profit 32.0% Margin 30.0% Target: 28-31% 29.1% 28.5% 28.1% 28.0% 26.0% 25.5% 24.9% 24.8% Gross Margin 24.0% Target – 28% to 31% 22.0% Operating Leverage from Mix Shift + Acquisition 20.0% synergies + Efficiencies 18.0% 2020 2021 2022 2023 2024 Q1 2025 23
Slide 24: Adjusted Operating Margin
Adjusted* Operating 20.0% Target: 17-20% 18.3% Margin 15.9% 17.4% 15.0% 13.8% 11.1% 10.3% 10.0% Adjusted Operating Margin Target - 17% to 20% 5.0% Operating leverage from mix shift + acquisition synergies + efficiencies 0.0% 2020 2021 2022 2023 2024 Q1 2025 *See non-GAAP reconciliation on slide 32 2
Slide 25: UFP Historical Stock Performance
12000% 10000% 8000% 6000% 7497% UFP Historical 4000% Stock 2000% Performance 0% 398% 20 Years 237% UFP Technologies (UFPT) Price % Change Russell 2000 (RUT) Price % Change S&P 500 (SPX) Price % Change *Measured as the percent increase from June 06, 2005 through June 04, 2025 25
Slide 26: R. Jeffrey Bailly, Chairman, CEO & President
R. Jeffrey Bailly Chairman, CEO & President Newburyport, Massachusetts Ronald Lataille CFO, Sr. VP & Treasurer Newburyport, Massachusetts UFP Technologies Newburyport, MA 01950 www.ufpt.com 100 Hale St. 978-352-2200 investorinfo@ufpt.com
Slide 27: Appendix: Reconciliation of Non-GAAP Results
Appendix Reconciliation of Non-GAAP Results (in Millions) 2020 2021 2022 2023 2024 Q1 2025 Revenue, As Reported $ 179.4 $ 206.3 $ 354.0 $ 400.1 $ 504.4 $ 148.1 Operating Income, as Reported 16.7 21.2 55.4 55.7 80.9 23.1 Add: Purchase Accounting Expenses - - - - 1.1 - Add: Acquisition Related Costs -